Brentuximab vedotin for the treatment of CD30+lymphomas

Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.

(2017) F. M. Foss et al.   JOURNAL OF CLINICAL ONCOLOGY

Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series.

(2017) N. Bartlett et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

(2010) N. Schmitz et al.   BLOOD

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

(2010) Greg Dueck et al.   CANCER

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors in lymphoma

(2010) Amanda Copeland et al.   CURRENT OPINION IN ONCOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

(2009) Michael Dickinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

(2009) Andres Forero-Torres et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

(2009) Boris Böll et al.   BRITISH JOURNAL OF HAEMATOLOGY

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

(2009) Ulrike Heider et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

(2009) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

(2009) Q-L Zhang et al.   LEUKEMIA

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience

(2008) Andy I. Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

(2008) K. J. Savage et al.   BLOOD

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

(2008) Ezogelin Oflazoglu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire

(2008) Steven Le Gouill et al.   JOURNAL OF CLINICAL ONCOLOGY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET